Has Lee Kaplan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,211,258 in general payments to Lee Kaplan, MD across 497 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lee Kaplan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lee Kaplan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lee Kaplan, MD

Gastroenterology · Lebanon, NHNPI 1255322475

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $895,188 of the $1,211,258 with a category attached, or 73.9%. 22 manufacturers reported payments, led by Novo Nordisk at 43.2% of the total. Reporting peaked in 2019 at $439,249 and has fallen 68.4% since, to $138,973 in 2025. Among gastroenterology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,211,258in general payments, 2019–2025

Across 497 payments — averaging $2437.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$524K
Novo Nordisk AS$201K
Pfizer$119K
Eli Lilly$92K
Boehringer Ingelheim International GmbH$91K
Boehringer Ingelheim$83K
plus $102K from 16 others

$18,978in research payments, 2019–2025

Across 2 payments — averaging $9488.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$11K
Boehringer Ingelheim International GmbH$8K

What the payments were for

Consulting fees$895,18874%
Speaking & faculty fees$72,3646%
Travel & lodging$229,70319%
Food & beverage$13,9631%
Education$400%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	104	$523,775
Novo Nordisk AS	35	$200,502
Pfizer	17	$119,133
Eli Lilly	109	$91,845
Boehringer Ingelheim International GmbH	71	$91,162
Boehringer Ingelheim	73	$82,587
Novo Nordisk Health Care AG	3	$21,174
Medical Device Business Services, Inc.	27	$18,993
Amgen	7	$15,981
Perspectum Diagnostics Ltd	1	$14,558
AstraZeneca	9	$9,154
Rhythm Pharmaceuticals, Inc.	3	$6,303
Boehringer Ingelheim Espana S.A.	2	$6,124
Genentech USA, Inc.	3	$3,448
Gilead	2	$3,061
Lilly USA, LLC	22	$2,017
Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C.	2	$693
Johnson & Johnson(2 entities)	2	$244
Covidien LP	2	$189
Madrigal Pharmaceuticals	1	$141
Astrazeneca UK Limited	1	$135
Baxter Healthcare	1	$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,211,258 in reported general payments places this provider in the 95th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$2,414

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Lebanon

Corey SiegelLebanon$602K
Brian LacyLebanon$177K
Shelby SullivanLebanon$137K
Michael WinterLebanon$58K
Stuart GordonLebanon$42K
Timothy GardnerLebanon$17K
Liam ZakkoLebanon$5K
Michael CurleyLebanon$4K
Nicholas HannonLebanon$3K
Leon McLeanDerry$171K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →